ALK | GenomeWeb


Data from the meeting suggest that lung cancer patients with ALK-positive tumors may soon have two first-line options and more choices when their disease progresses.

Genentech's Alecensa and AstraZeneca's Tegrisso are the latest precision lung cancer drugs, and Xalkori might soon be an option for a new molecular subpopulation.

The preliminary results showed that 76 percent of study subjects under 40 had druggable mutations.

In developing the recommendations, the expert panel attempted to keep up with the fast-moving advances in oncology.

The anti-PD-L1 drug significantly extended survival in NSCLC patients with high PD-L1 expression compared to docetaxel, while alectinib shrank tumors for those with ALK-positive tumors and brain metastases.

Zykadia received conditional marketing authorization as a treatment for advanced NSCLC patients who've previously received the ALK inhibitor Xalkori, and so are known to be ALK positive.

Entrectinib is Ignyta's lead product that the biotech is investigating in patients with tumors characterized by TrkA, TrkB, TrkC, ROS1, and ALK markers.

NEW YORK (GenomeWeb) – For patients who have ALK-positive, advanced non-small cell lung cancer tumors and have stopped responding to Pfizer’s Xalkori (crizotinib), the US Food and Drug Administration this week approved a new option from Novartis called Zykadia (ceritinib).

Originally published Oct. 29.


The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.